Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Zacks Investment Research on MSN

MRNA stock jumps to 52-week high on expansion plans beyond vaccines

Shares of Moderna MRNA rose nearly 13% on Friday after the company unveiled a long-term strategy to transform itself from a ...
MarketBeat on MSN

Short Squeeze Alert-Moderna Stock Surges on New Strategy

Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...